News & Updates
Showing Respirology articles
Showing
Show Multimedia Only

Amivantamab plus chemo improves survival in advanced NSCLC
03 Feb 2024
byStephen Padilla
Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.
03 Feb 2024








